Also, the high expression of HBXIP in HBV-related GC patients has led to higher drug resistance in tumor cells [143], which might bring primary resistance to the immunotherapy [169], decreasing the effectiveness of immune checkpoint inhibitors for HBXIP+ GC patients [170]. The gene discussed is LAMTOR5; the disease is neoplasm.